AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37401993
Drug: Co-encapsulated antiretrovirals
RxNorm normalized name: poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-encapsulated antiretrovirals (ARVs) with ingestible sensor (IS) pills from baseline through week 16.
Trial: 37402024
Drug: Nasal esketamine
RxNorm normalized name: esketamine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal esketamine (56 mg) after pretreatment with nasal oxymetazoline (0.05%)
Trial: 37402024
Drug: Nasal esketamine
RxNorm normalized name: esketamine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal esketamine (56 mg) after 16 consecutive days of mometasone (200 µg)
Trial: 37402024
Drug: Nasal esketamine
RxNorm normalized name: esketamine Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal esketamine (56 mg)
Trial: 37402144
Drug: THRIVE intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THRIVE intervention (cognitive behavioral app used daily over 21 days with weekly telephone coaching)
Trial: 37402153
Drug: ViTT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ViTT vaccine
Trial: 37402153
Drug: ViPS vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ViPS vaccine
Trial: 37402153
Drug: Control meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meningococcal vaccine
Trial: 37402281
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for vulvovaginal discomfort
Trial: 37402471
Drug: Dual oral
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual oral metronomic vinorelbine and capecitabine (mNC) regimen: oral vinorelbine (VNR) 40 mg three times weekly and capecitabine (CAP) 500 mg three times a day
Trial: 37402471
Drug: Dual oral
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual oral metronomic vinorelbine and capecitabine (mNC) regimen
Trial: 37402852
Drug: Treatments improving
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatments improving anhedonia and normalizing brain reward function
Trial: 37402864
Drug: Methadone-exposed children
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone-exposed children with pharmacological treatment for NAS/NOWS (n=47)
Trial: 37402864
Drug: Methadone-exposed children
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone-exposed children without pharmacological treatment for NAS/NOWS (n=51)
Trial: 37403057
Drug: MAPS+ (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAPS+ (6 proactive MAPS-based counseling calls over 12 months plus a 24-month digital treatment adjuvant)
Trial: 37403159
Drug: Low-dose risperidone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose risperidone in combination with sertraline (RS group)
Trial: 37403159
Drug: Regular-dose risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regular-dose risperidone (control group)
Trial: 37404205
Drug: Faster Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faster Insulin Aspart
Trial: 37404205
Drug: Standard Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Insulin Aspart
Trial: 37404855
Drug: High-dose n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose n-3 (EPA + DHA) supplementation
Trial: 37404855
Drug: High-dose n-6
RxNorm normalized name: 18:3 (n-6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose n-6 (LA) supplementation
Trial: 37405334
Drug: Vasodilator drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilator drugs
Trial: 37405504
Drug: Qualitative CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualitative CT scan analyses with simple clinical and biological parameters
Trial: 37405662
Drug: Anti-infective therapy
RxNorm normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-infective therapy along with a mixture of allografts with or without a collagen barrier membrane
Trial: 37405785
Drug: Fucoxanthin 12
RxNorm normalized name: Fucoxanthin
DrugBank: Fucoxanthin (DB15462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fucoxanthin 12 mg once a day for 12 weeks
Trial: 37406106
Drug: Pembrolizumab, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, trastuzumab, and chemotherapy (PTC)
Trial: 37406251
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH (0.034 mg/kg/d)
Trial: 37406769
Drug: High 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High 1000 mg daily prenatal DHA supplement
Trial: 37406769
Drug: Low 200
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low 200 mg daily prenatal DHA supplement
Trial: 37406777
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of VLA2001
Trial: 37406777
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of VLA2001 in VLA2001-primed participants
Trial: 37406777
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of VLA2001 in ChAdOx1-S-primed participants
Trial: 37407040
Drug: Calcium Soft
RxNorm normalized name: CVS Calcium Soft Chew (Caramel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Soft Chew D3 and a multivitamin supplement (MVS) specifically developed according to the type of operation; oesophagectomy group receives Multi-E, gastrectomy group receives Multi-G. MVSs taken once daily, Calcium Soft Chew D3 two times per day.
Trial: 37407059
Drug: Global School-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Global School-based Student Health Survey (GSHS) administered to students.
Trial: 37407096
Drug: Digital cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital cognitive behavioural therapy for insomnia (n=48)
Trial: 37407142
Drug: Dasatinib plus
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib plus EsPhALL chemotherapy
Trial: 37407142
Drug: Imatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib plus chemotherapy
Trial: 37407326
Drug: CYP2D6 genotype-guided
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6 genotype-guided metoprolol administration
Trial: 37814224
Drug: Goal-directed hemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed hemodynamic therapy (GDHT)
Trial: 37408075
Drug: Cefepime/zidebactam (WCK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime/zidebactam (WCK 5222) administered under compassionate use
Trial: 37408075
Drug: Polymyxins (failed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxins (failed treatment)
Trial: 37409159
Drug: GH001 (5-methoxy-N,N-dimethyltryptamine)
RxNorm normalized name: 5-methoxy-N-acetyltryptamine
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GH001 (5-methoxy-N,N-dimethyltryptamine) 12 mg
Trial: 37409159
Drug: GH001 (5-methoxy-N,N-dimethyltryptamine)
RxNorm normalized name: 5-methoxy-N-acetyltryptamine
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GH001 (5-methoxy-N,N-dimethyltryptamine) 18 mg
Trial: 37409159
Drug: GH001 (5-methoxy-N,N-dimethyltryptamine)
RxNorm normalized name: 5-methoxy-N-acetyltryptamine
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GH001 (5-methoxy-N,N-dimethyltryptamine) individualized dosing
Trial: 37409229
Drug: Ladarixin (LDX)
RxNorm normalized name: Ladarixin
DrugBank: Ladarixin (DB16212)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ladarixin (LDX) 400 mg twice daily for three cycles of 14 days on/14 days off
Trial: 37409757
Drug: Betaine supplementation
RxNorm normalized name: betaine
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine supplementation (2.5 and 5.0 g/d)
Trial: 37409992
Drug: Adjunctive Transcoronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Transcoronary Pacing Strategy
Trial: 37410050
Drug: Calcipotriene-Betamethasone Dipropionate
RxNorm normalized name: Betamethasone Dipropionate/Calcipotriene 0.064%-0.005% Topical application Ointment [CALCIPOTRIENE-BETAMETHASONE DIPROPIONATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) cream
Trial: 37410050
Drug: Calcipotriene-Betamethasone Dipropionate
RxNorm normalized name: Betamethasone Dipropionate/Calcipotriene 0.064%-0.005% Topical application Ointment [CALCIPOTRIENE-BETAMETHASONE DIPROPIONATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene-Betamethasone Dipropionate (CAL/BDP) topical solution
Trial: 37410421
Drug: Low-dose mindfulness
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mindfulness comparator (LDC)
Trial: 37410465
Drug: Risk-stratified care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk-stratified care (physiotherapy treatment tailored for risk category)
Trial: 37410740
Drug: Medication purchased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication purchased in the informal sector
Trial: 37410740
Drug: Medication purchased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication purchased in the formal sector
Trial: 37410740
Drug: Antibiotic usage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic usage in the informal sector
Trial: 37413896
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (n = 41)
Trial: 37414060
Drug: ARI0002h (BCMA-directed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARI0002h (BCMA-directed CAR T-cell therapy)
Trial: 37414066
Drug: Cabamiquine 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine 60 mg
Trial: 37414066
Drug: Cabamiquine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine 80 mg
Trial: 37414066
Drug: Cabamiquine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine 100 mg
Trial: 37414066
Drug: Cabamiquine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine 200 mg
Trial: 37414066
Drug: Cabamiquine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine 30 mg
Trial: 37414066
Drug: Cabamiquine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine 30 mg, 60 mg, 80 mg
Trial: 37414066
Drug: Cabamiquine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabamiquine (all doses)
Trial: 37414137
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor inhibitor (TNFi)
Trial: 37414215
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab 200 mg IV followed by 1 year of adjuvant pembrolizumab
Trial: 37414460
Drug: PAXI (Patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAXI (Patient advice plus exercise plus corticosteroid injection)
Trial: 37414702
Drug: Positron emission
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron emission tomography/computed tomography (PET/CT) with 296 MBq injection
Trial: 37414705
Drug: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense methotrexate-vinblastine-adriamycin-cisplatin (ddMVAC)
Trial: 37414899
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) plus PD-1 inhibitors (nivolumab or pembrolizumab)
Trial: 37414899
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (FMT plus PD-1 inhibitors)
Trial: 37414923
Drug: Tenofovir-based antiretroviral
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir-based antiretroviral therapy (tenofovir, lamivudine, efavirenz)
Trial: 37415100
Drug: Surgery (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery (11 as primary treatment and 4 during follow-up)
Trial: 37415100
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection or platelet rich plasma injection
Trial: 37415239
Drug: DZD1516 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZD1516 monotherapy at 250 mg, twice daily (BID)
Trial: 37415239
Drug: DZD1516 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DZD1516 monotherapy
Trial: 37415246
Drug: Adjunctive lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive lifestyle intervention
Trial: 37415648
Drug: Combined Therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Therapy (CT) - oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day
Trial: 37415712
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (cognitive stimulation and occupational activities)
Trial: 37415845
Drug: Camrelizumab 200
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab 200 mg every 3 weeks and famitinib 20 mg once per day
Trial: 37417239
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) after 1 pass
Trial: 37417239
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) after 2 passes
Trial: 37417239
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) after 3 to 7 passes
Trial: 37417239
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy (EVT) with failed reperfusion
Trial: 37417619
Drug: Dialyzable leukocyte
RxNorm normalized name: Dialyzable leukocyte extract
DrugBank: Dialyzable leukocyte extract (DB16530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialyzable leukocyte extract (DLE) administered orally at 2 mg per day for 5 days, followed by 4 mg per week for 5 weeks, and then 2 mg per week for 5 weeks.
Trial: 37417824
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors
Trial: 37417824
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin receptor-neprilysin inhibitors+beta-blocker+mineralocorticoid receptor antagonist)
Trial: 37417948
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy to MRSI metabolic abnormalities, tumor bed, and residual contrast enhancements, with concomitant Temozolomide for 6 months.
Trial: 37417948
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) of 60 Gy with concomitant Temozolomide for 6 months.
Trial: 37417948
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy.
Trial: 37417948
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) of 60 Gy.
Trial: 37417948
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Trial: 37417948
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Trial: 37417970
Drug: Combined Platelet-Rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Platelet-Rich Plasma Noncrosslinked Hyaluronic Acid Injections
Trial: 37418059
Drug: Personal Analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal Analgesic Sufficiency Status (PASS) measured by pre-tetanus-induced ANI variation
Trial: 37418059
Drug: Sevoflurane and
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane and increased effect-site concentrations of remifentanil (2, 4, 6 ng/ml)
Trial: 37418263
Drug: Erythropoietin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin treatment (1000 U/kg/dose on days 1, 2, 3, 4, and 7)
Trial: 37418498
Drug: iCARE Nigeria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCARE Nigeria HIV treatment support intervention (peer navigation and SMS text message medication reminders)
Trial: 37418583
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of injectable-platelet-rich fibrin (i-PRF) and type-1 collagen particles applied to the defect in adjunct to periapical surgery (n=19)
Trial: 37418643
Drug: Targeted molecular
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted molecular therapy
Trial: 37418685
Drug: Rituximab and
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab and lenalidomide (R2) combination therapy: 20 mg oral lenalidomide from days 2 to 22 and IV rituximab 375 mg/m2 on day 1 for a maximum of 6 cycles.
Trial: 37418685
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of lenalidomide at 10 mg/d from days 1 to 21 for every 28 days for a total of 12 cycles after achieving partial or complete response.
Trial: 37419129
Drug: Alum-adjuvanted 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted 12 μg
Trial: 37419129
Drug: Alum-adjuvanted 48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted 48 μg
Trial: 37419129
Drug: Alum-adjuvanted 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alum-adjuvanted 90 μg
Trial: 37419129
Drug: Non-adjuvanted 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted 12 μg
Trial: 37419144
Drug: Amikacin liposome
RxNorm normalized name: AMIKACIN LIPOSOME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin liposome inhalation suspension (ALIS) 590 mg added to background multidrug therapy for 12 months
Trial: 37419144
Drug: Amikacin liposome
RxNorm normalized name: AMIKACIN LIPOSOME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin liposome inhalation suspension (ALIS) 590 mg
Trial: 37419144
Drug: Amikacin liposome
RxNorm normalized name: AMIKACIN LIPOSOME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin liposome inhalation suspension (ALIS) with clofazimine or clofazimine plus azithromycin
Trial: 37419633
Drug: treatment-as-usual waitlist
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment-as-usual waitlist control group
Trial: 37419638
Drug: Ivermectin mass
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin mass drug administration (MDA) combined with artemisinin-based combination therapy (ACT)
Trial: 37420006
Drug: IL-1β-neutralizing antibody
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1β-neutralizing antibody canakinumab
Trial: 37420013
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for dizziness